AMAG Key Stats
|Revenue (Quarterly YoY Growth)||21.84%|
|EPS Diluted (TTM)||-0.4519|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-9.634M|
|Gross Profit Margin (Quarterly)||88.22%|
|Profit Margin (Quarterly)||-0.67%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- Theravance (THRX) in Focus: Stock Adds 5.0% - Tale of the Tape Zacks Dec 9
- BioMarin Seeks Canadian Approval Dec 5
- Oculus Gains on Scar Product Approval - Analyst Blog Zacks Dec 5
- MYGN Unveils Prolaris Study Results - Analyst Blog Zacks Dec 5
- BioMarin Seeks Canadian Approval - Analyst Blog Zacks Dec 5
- AMBI Plunges on Disappointing FDA News - Analyst Blog Zacks Dec 5
- Positive Data on ChemoCentryx Candidate - Analyst Blog Zacks Dec 5
- Cytokinetics Progresses with Tirasemtiv - Analyst Blog Zacks Dec 5
- Affymetrix Remains Outperform Dec 4
- MYGN Battles Odds, Shares Fall Dec 4
AMAG Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). AMAG Pharmaceuticals is up 71.01% over the last year vs S&P 500 Total Return up 29.87%, Actelion up 63.98%, and Isis Pharmaceuticals up 320.4%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for AMAG
Pro Report PDF for AMAG
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download AMAG Pro Report PDF
Pro Strategies Featuring AMAG
Did AMAG Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
AMAG Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of Feraheme® (ferumoxytol) Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA.